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Abstract 
Accumulating evidence suggests that platelet-type 12-lipoxygenase (p12-LOX) plays an important 
role in tumor development.  However, how p12-LOX contributes to tumorigenesis is still not 
understood yet.  The role of p12-LOX was therefore examined in tumor promotion using mouse 
epidermal JB6 P+ cells that are sensitive to 12-O-tetradecanoylphorbol-13-acetate(TPA)-induced 
transformation.  The expression of p12-LOX was significantly higher in JB6 P+ cells than in JB6 P− 
cells that were resistant to transformation, and its expression was further increased by tumor necrosis 
factor (TNF)-α.  Importantly, the inhibition of p12-LOX in JB6 P+ cells by baicalein, a specific 
inhibitor or small interfering RNA significantly suppressed TPA-induced transformation.  Moreover, 
treatment with 12(S)-hydroxyeicosatetraenoic acid (HETE), a metabolite of p12-LOX, enhanced 
TPA-induced neoplastic transformation either in the presence or absence of baicalein.  These results 
indicate that p12-LOX is required for tumor promotion of epidermal cells and that 12(S)-HETE 
functions as a rate-limiting factor.  Notably, treatment with baicalein significantly suppressed the 
proliferation of JB6 P+ cells when cells were seeded at a low density in a culture plate.  Moreover, 
the cloning efficiency of JB6 P+ cells was dramatically decreased by inhibition of p12-LOX.  In 
contrast, baicalein treatment did not affect the cloning efficiency of most malignant cancer cells.  
These results indicate that p12-LOX is induced by the inflammatory cytokine TNF-α in the early 
stage of tumorigenesis, and is required for tumor promotion through enhancing efficient proliferation 
of a small number of initiated cells.  The present results suggest that the p12-LOX pathway may be 
an effective target of chemoprevention for skin carcinogenesis.  
1 
Piao et al. 
Introduction 
The cyclooxygenase (COX) and lipoxygenase (LOX) are two important enzyme classes that 
metabolize polyunsaturated fatty acids and play important roles in tumorigenesis (1).  COX-2, one 
of the COX isoenzymes, plays a variety of pathological roles including cancer development (2).  
Previous studies have demonstrated that the induction of COX-2 is responsible for intestinal 
tumorigenesis (3) and that prostaglandin (PG)E2, one of downstream products of COX-2, is 
required for carcinogenesis in the stomach through cross-talk with activated Wnt signaling (4,5).   
Among the LOX family members, it has been suggested that platelet-type (p12-LOX) plays 
an important role in tumorigenesis (6,7).  The expression of p12-LOX is absent or at a basal level in 
the normal tissues (6,8).  However, the induction of p12-LOX is widely found in human cancer 
tissues that develop in the colon (9), prostate (10,11), stomach (12), and skin (13).  In animal 
models, the p12-LOX expression is also found in xenografts of melanoma (9) and in skin tumors 
developed by an initiation/promotion protocol (14).  Moreover, it has been shown that p12-LOX 
expression is associated with the advanced stages of human prostate cancer and its levels increase 
in metastasized tumors in a mouse model (10,11).  These analyses suggest that p12-LOX 
contributes to development and progression of various types of cancers.   
The treatment of cancer cells with baicalein, a p12-LOX inhibitor, has also been shown to 
result in the induction of apoptosis and inhibition of tumor xenograft growth in immunodeficient 
mice (13,15-17).  Consistently, the forced expression of the p12-LOX gene or stimulation with 
12(S)-HETE, a metabolite of p12-LOX, has been shown to induce cell proliferation and survival 
(16,18,19).  Moreover, it has been reported that p12-LOX induces cell spreading, 
integrin-dependent cell survival (19,20) and angiogenesis through the induction of vascular 
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endothelial growth factor (VEGF) expression (21,22).  Accordingly, it is conceivable that the 
p12-LOX pathway also contributes to tumor progression through the acceleration of cell survival, 
migration and angiogenesis. 
Genetic experiments have indicated that p12-LOX plays an important role in skin 
tumorigenesis.  In the initiation/promotion skin carcinogenesis model, multiplicity and incidence of 
squamous cell carcinoma are suppressed significantly by the disruption of the p12-LOX gene (23).  
Accordingly, it is possible that p12-LOX is important for tumor promotion of the initiated cells 
during skin carcinogenesis.  To assess this possibility, we have investigated the role of p12-LOX 
and 12(S)-HETE in promotion of epidermal cell transformation using mouse JB6 P+ cell line.  The 
cells of this line are transformed by stimulation with tumor promoters such as TPA or TNF-α, and 
therefore, are useful to examine the mechanisms involved in the promotion of epidermal cell 
transformation (24,25).  Clonal variant JB6 P− cells are resistant to tumor promoter-induced 
transformation.  As a result, we therefore used JB6 P− cells, in addition to P+ cells, to examine the 
role of p12-LOX in the transformation process.   
We demonstrate here that expression of p12-LOX is increased significantly in JB6 P+ cells 
but not in JB6 P− cells.  Moreover, inhibition of p12-LOX of JB6 P+ cells suppresses colony 
formation in soft agar, while treatment with 12(S)-HETE accelerates it.  In addition, we show that 
the p12-LOX pathway is responsible for proliferation from a single cell or a small number of cells.  
These results suggest that p12-LOX contributes to tumor promotion through the acceleration of 
initiated cell proliferation, and that lack of p12-LOX is thus considered to be one of the causes for 
the resistance of JB6 P− cells against tumor promoter-induced transformation.   
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Materials and methods 
Reverse transcription–polymerase chain reaction analysis 
RNA samples were prepared from cultured cells or mouse tissue samples using the ISOGEN 
solution (Nippongene, Tokyo, Japan).  Mouse gastric tumors and intestinal polyps were obtained 
from K19-Wnt1/C2mE mice (6) and ApcΔ716 mice (26), respectively.  Control tissues were 
obtained from normal tissues of the same mice or wild-type mice.  Extracted RNA was 
reverse-transcribed and amplified by PCR with the following primer set: p12-LOX 
(F-5’-GCGGTCTTCGAATTGAACTT-3’, and R-5’-CAGGAACAGTGTTGGAGCTG-3’); 
epidermal-type 12-LOX (F-5’-CAGGAGCTGGAGAACAGAAGG-3’, and 
R-5’-GAACTGGTACCCAAAGAGAGCATC-3’); leukocyte-type 12-LOX 
(F-5’-GGCTCCAACAACGAGGTCTA-3’, and R-5’-AGTTCCTCCTCCCTGTGGTT-3’); 
5-LOX (F-5’-AATGGAGGTGGTGAGCATCTA-3’, and 
R-5’-TCCTTCACTGGCTTCTCAATG-3’); 8-LOX 
(F-5’-CGAAATGCAGGGTGAGAGTA-3’, and R-5’-TCCTGCAGTGTAGGGTGATG-3’).  
Animal experiments were carried out according to the protocol approved by the Committee on 
Animal Experimentation on Kanazawa University. 
 
Cell culture and soft agar colony formation assay  
JB6 P+ (Cl 41-5a) and JB6 P− (Cl 30-7b) cells were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA).  The cells were cultured in MEM supplemented with 5% FBS 
and incubated in a 5% CO2 at 37oC.  For the soft agar colony formation assay, JB6 P+ and P− cells 
were exposed to TPA (Calbiochem, San Diego, CA) at 10 ng/ml in 1 ml of basal medium eagle 
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(Invitrogen, Grand Island, NY) with 10% FBS and 0.33% agar, and then seeded in a 6-well plate 
(104 cells/well).  Soft agar cultures were maintained in a 5% CO2 incubator at 37oC for 14 days, 
stained with Giemsa stain solution (Wako, Osaka, Japan), and the number of colonies was scored 
using a stereomicroscope and Image J software program (NIH).  A nonselective LOX inhibitor 
NDGA, a selective 12-LOX inhibitor baicalein (Tocris Biosciences, Ellisville, MI), or a selective 
5-LOX inhibitor AA-861 (Sigma, St. Louis, MO) was added to the agar containing medium at 5 
μM (NDGA and baicalein) or 10 μM (AA-861) to test their inhibitory effect on anchorage 
independent transformation.  To examine the effect of 12(S)-HETE, cells were pre-treated with 
12(S)-HETE (Cayman Chemical, Ann Arbor, MI) at 0.1 μM or 1 μM for one day prior to 
stimulation with TPA, and were plated as described above for the soft agar colony formation 
assay.  All soft agar colony formation assays were repeated three times, and the mean colony 
numbers and S.D. were calculated. 
 
Subcutaneous transplantation of tumor cells to mice 
JB6 P+ cells were stimulated with TPA at 10 ng/ml for 12 h and inoculated s.c. at 1.0 × 106 cells/site 
to 3 sites per mouse for four mice each for drug-treated and no-treated group (Balb/c-nu/nu: 
Charles River Laboratories Japan, Tokyo, Japan).  At 5 days after inoculation, 50 μl of TPA (10 
ng/ml in PBS) was injected s.c. into the inoculation site.  After palpable tumors developed, 
baicalein was administered at 20 mg/kg/day in 0.5% methylcellulose (Wako) p.o., and treatment 
was continued for 14 days.  In another dosing experiment, baicalein treatment started from day 7 
after cell inoculation, and the treatment was continued until 1 week after palpable tumors 
developed in the control mice.  The dosing protocol has been reported to inhibit p12-LOX activity 
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in vivo (27).  The tumor size was measured every 2 days during drug treatment using 6 developed 
tumors for each experiment and the mean tumor volume and standard error were calculated. 
 
BrdU labeling analysis 
Mice were injected i.p. with 100 μl of BrdU solution (BD Pharmingen, San Diego, CA) at 1 h 
before euthanasia.  The tumor tissues were fixed in 4% paraformaldehyde, embedded and 
sectioned at 4-μm thickness.  These sections were stained with anti-BrdU antibody (BD 
Pharmingen).  The immunostaining analysis was repeated three times. 
 
Small interfering RNA transfection 
The target sequence of three small interfering RNAs (siRNAs) against p12-LOX were: A, sense: 
GGGUGCAGGGAGAGGGAAUTT, antisense: AUUCCCUCUCCCUGCACCCTT; B, sense: 
GGAUGGAAUUCCAGCUAAUTT, antisense: AUUAGCUGGAAUUCCAUCCTT; and C, 
sense: CAUCUCAGAUGGAGGAAUATT, antisense: UAUUCCUCCAUCUGAGAUGTT.  
We confirmed the siRNA sequences to be specific for mouse p12-LOX by GenBank database 
search.  There is no transcript in the database which has >80% homology with siRNA sequences 
except for p12-LOX.  These three siRNAs (A, B, and C) were mixed and transfected into JB6 P+ 
cells at 50 nM using siFECTOR (B-Bridge, Sunnyvale, CA. USA) prior to TPA stimulation.  A 
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Cells were collected in buffer and sonicated.  After centrifugation at 20,000g, 20 μg of the 
supernatant was separated in a 10% sodium dodecy sulfate polyacrylamide gel. Antibody for 
12-LOX (Santa Cruz Biotechnology, Carlsbad, CA, USA) was used as the primary antibody.  The 
ECL detection system (Amersham Biosciences, Buckinghamshire, UK) was used to detect the 
specific signals. 
 
NF-κB activation assay 
JB6 P+ and JB6 P− cells were stimulated with TNF-α (Calbiochem) at 10 ng/ml in the presence or 
absence of baicalein (Tocris Biosciences) at 5 μM, and the nuclear extract of these cells was 
prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (PIERCE, Rockford, IL).  
Activity of NF-κB was measured using NF-κB p65 Transcription Factor Assay Kit (Active Motif, 
Carlsbad, CA).   
 
Cell proliferation assay 
The cell proliferation rate was determined using an 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay kit (Nacalai Tesque, 
Kyoto, Japan) according to the manufacturer’s protocol.  Briefly, 102 or 103 cells were plated to 
each well of a 96-well microplate, cultured overnight, and the cells of the drug-treated group were 
treated with NDGA (5 μM) or baicalein (5 μM).  Following the drug-exposure period (4 or 6 
days), 10 μl of MTT (5 mg/ml in PBS) was added to each well, and then the cells were cultured 
further for 4 h.  The formazan crystals that were produced by these cultures were solubilized using 
100 μl of isopropyl alcohol containing hydrochloric acid at 40 mM, and the absorbance at 570 nm 
was measured.  All experiments were repeated three times and the mean relative MTT assay 
results to the no-drug control groups were then calculated and presented.  
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Cloning efficiency assay 
JB6 P+ cells, two gastric cancer cells: AGS (American Type Culture Collection) and Kato-III 
(Cell Resource Center for Biomedical Research, Tohoku Univ., Japan), and three colon cancer 
cells: HCT-116 (ATCC), DLD-1 and SW480 (Cell Resource Center for Biomedical Research) 
were used for the cloning efficiency experiments.  The gastrointestinal cancer cells were 
maintained in Roswell Park Memorial Institute  (AGS, Kato-III and DLD-1) or Dulbecco’s 
modified Eagle’s medium (SW480 and HCT-116) supplemented with 10% fetal bovine serum 
and cultured in a 5% CO2 incubator at 37oC.  The cells were suspended in the medium at 10 
cells/ml, and 100 μl was dispensed to each well of 96-well microplate to expect plating a single 
cell in each well.  To examine the effect of p12-LOX on cloning efficiency, siRNA for p12-LOX 
was transfected prior to TPA stimulation, or baicalein was added to the medium at 5 μM.  After 
culture for 14 days, all wells were stained with Giemsa stain solution (Wako).  All experiments 
were repeated three times and the cloning efficiency was calculated by dividing the number of 
wells containing proliferating cells with the total number of cell-plated wells. 
 
Statistical analysis 
The statistical significance of differences was determined by Student’s t-test.  Differences with a 
value of P < 0.05 were considered to be significant. 
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Results 
Increased expression of p12-LOX in promotion-sensitive JB6 P+ cells 
The expression level of p12-LOX was first examined by RT-PCR in the promotion-sensitive JB6 
P+ cells as well as in promotion-resistant JB6 P− cells.  The level of p12-LOX mRNA in the JB6 
P+ cells was significantly higher than that in the JB6 P− cells (Figure 1A).  Stimulation with TPA 
at 10 ng/ml increased the p12-LOX expression level in JB6 P− cells, although its highest level at 
12 h was lower than that of the basal level of JB6 P+ cells.  In contrast, p12-LOX in the 
TPA-stimulated JB6 P+ cells was increased only slightly possibly caused by constitutive 
elevation of the basal level.  No significant differences were observed in either the expression of 
other LOX family members, such as epidermal-type (e)12-LOX, leukocyte-type (l)12-LOX, 
5-LOX, and 8-LOX between JB6 P+ cells and JB6 P− cells (Figure 1A). 
 
Suppression of anchorage independent transformation of JB6 P+ cells by inhibition of p12-LOX  
TPA treatment induced soft agar colony formation of JB6 P+ cells but not of JB6 P− cells that are 
a resistant line to tumor promoter-induced transformation (Figure 1B).  When JB6 P+ cells were 
treated with a non-specific LOX inhibitor NDGA at 5μM, the number of soft agar colonies 
decreased significantly by 88%.  Moreover, treatment with baicalein, a p12-LOX specific 
inhibitor, at 5 μM also suppressed colony formation in soft agar of JB6 P+ cells by 81% (Figure 
1B and C).   It has been suggested that 5-LOX is also procarcinogenic lipoxygenase among the 
LOX family members (1,6).  However, treatment with AA-861, a 5-LOX specific inhibitor, at 10 
μM did not reduce the number of soft agar colonies (Figure 1B and C).  These results indicate that 
p12-LOX but not 5-LOX plays an important role in the neoplastic transformation of JB6 P+ cells.   
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Baicalein has been reported to be a potent inhibitor of both reticulocyte 15-LOX and 
p12-LOX (28).  Therefore, the effects of p12-LOX inhibition on soft agar colony formation were 
examined using a specific siRNA.  Transient transfection of siRNA against the p12-LOX gene 
reduced the mRNA level in comparison with that of control cells (Figure 1D).  We also confirmed 
the protein level of p12-LOX to have decreased in the siRNA transfected JB6 cells (Figure 1E).  
Importantly, the inhibition of p12-LOX in JB6 P+ cells by siRNA transfection caused a 
significant suppression of TPA-induced neoplastic transformation by 61% compared with that in 
the control cells (Figure 1C).  Therefore, the siRNA experiments confirmed the role of p12-LOX 
in promotion step of JB6 P+ cell transformation. 
 
p12-LOX independent growth of TPA-induced JB6 P+ tumors in nude mice 
We examined the possibility that p12-LOX is required for the in vivo growth of tumor tissues 
consisting of JB6 P+ cells.  TPA-stimulated JB6 P+ cells formed palpable tumors in nude mice at 
22 days after subcutaneous inoculation (Figure 2A).  In contrast to the anchorage independent 
transformation assays, treatment of the mice with baicalein at 20 mg/kg/day from day 26 to 40 (14 
days) did not suppress tumor growth (Figure 2A and B).  There was no significant difference in 
the BrdU incorporation in tumor cells between baicalein-treated and non-treated mouse tumors 
(Figure 2C).  Moreover, tumor development was not suppressed when the baicalein treatment 
started from day 7 after tumor cell inoculation (Figure 2D).  These observations suggest that 
p12-LOX is less important for the JB6 tumor growth in vivo which develops from 106 inoculated 
cells.  Rather, p12-LOX appeared to play an important role in the proliferation from a single JB6 
cell (see below).   
10 
Piao et al. 
 
Acceleration TPA-induced transformation of JB6 P+ cells by 12(S)-HETE treatment  
We next examined the role of 12(S)-HETE, a metabolite of p12-LOX, in tumor promotion.  JB6 
P+ cells were pre-treated with 12(S)-HETE and the TPA-induced soft agar colony formation in 
the presence or absence of baicalein was examined.  Notably, the treatment of JB6 P+ cells with 
12(S)-HETE reversed the inhibitory effects of baicalein on TPA-induced colony formation in a 
dose-dependent manner (Figure 3A and B), thus indicating that 12(S)-HETE is responsible for 
tumor promotion of JB6 P+ cells. 
Importantly, even in the absence of baicalein, the number of TPA-induced soft agar 
colonies of JB6 P+ cells was significantly increased by treatment with 12(S)-HETE in a 
dose-dependent manner (Figure 3A and B).  In contrast, 12(S)-HETE treatment alone did not 
induce the soft agar colony formation of the TPA-untreated JB6 P+ cells.  These results, taken 
together, indicate that 12(S)-HETE is a rate-limiting factor for the promotion of JB6 P+ cell 
transformation, although stimulation by a tumor promoter, such as TPA, is still necessary for such 
promotion. 
 
Induction of p12-LOX by TNF-α stimulation 
JB6 P+ cells are also transformed by TNF-α stimulation, and TNF-α-activated NF-κB is 
important for neoplastic transformation of JB6 P+ cells (29,30).  Stimulation with TPA, acting 
through the MAP kinase pathway, activates AP-1 and subsequently NF-κB in JB6 P+ cells (31).  
Therefore, we examined the possibility that p12-LOX is involved in activation of NF-κB in the 
TNF-α-stimulated JB6 P+ cells.  Consistent with the findings of a previous report, the treatment 
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of JB6 P+ cells with TNF-α significantly increased the NF-κB activity (Figure 4A).  Notably, the 
treatment of the cells with baicalein did not affect the NF-κB activity in the TNF-α-stimulated 
cells, indicating that the p12-LOX pathway is not required for the activation of NF-κB.  Although 
NF-κB was activated by TNF-α in JB6 P− cells, the level was significantly lower than that in JP6 
P+ cells (Figure 4A).  We also confirmed that the TNF-α-induced NF-κB activation in JB6 P− 
cells was not suppressed by the baicalein treatment.  In contrast, stimulation with TNF-α induced 
the p12-LOX expression both in JB6 P+ and P− cells (Figure 4B), thus suggesting that p12-LOX 
is induced by inflammatory responses through the TNF-α/NF-κB pathway. 
 
Suppression of cell proliferation by inhibition of p12-LOX 
It has been shown that treatment with baicalein at 20 to 50 μM induces apoptosis and suppresses 
proliferation in several types of cancer cells (13,15-17).  Therefore, the MTT assay was used to 
determine whether the proliferation of JB6 P+ cells is suppressed by baicalein at 5 μM, the same 
concentration used in this study.  When 103 cells were plated in each well of a 96-well microplate, 
JB6 P+ cells showed approximately 20% decreased proliferation compared with that of the 
control cells both at day 4 and day 6 (Figure 5).  Treatment with NDGA at 5 μM also yielded a 
similar suppression of proliferation.   
Importantly, however, the proliferation of JB6 P+ cells was suppressed more significantly 
by baicalein or NDGA when 102 cells were plated in each well of a 96-well microplate (Figure 5).  
The number of drug-treated cells decreased by 90% of that of control cells at 6 days; the cells 
appeared to stop proliferation and they did not reach confluence after continuous culture for 
several days (data not shown).  These results suggest that p12-LOX is therefore essential for the 
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proliferation of JB6 P+ cells when cells were plated at a low density.  This is consistent with the 
results of the in vivo experiments (Figure 2C) showing that baicalein treatment did not affect cell 
proliferation in the established tumors, where the cell density was very high. 
 
Decrease of cloning efficiency of JB6 P+ cells by inhibition of p12-LOX 
These results prompted us to examine the possibility that p12-LOX is required for the 
proliferation from a solitary single cell.  Such ability of proliferation from a single cell is one of 
the important factors that are required for tumorigenesis.  The cloning efficiency of 
TPA-untreated or TPA-treated JB6 P+ cells were 54% and 44%, respectively (Figure 6B), 
indicating that the cloning efficiency was independent from TPA treatment.  Notably, the 
transfection of siRNA for p12-LOX suppressed the cloning efficiency significantly to 41% and 
31% in the TPA-untreated and TPA-treated JB6 P+ cells, respectively (Figure 6A and B).  More 
importantly, baicalein treatment dramatically reduced the cloning efficiency to 3% and 5% in the 
TPA-untreated and -treated cells, respectively.  These results indicate that p12-LOX is essential 
for the clonal proliferation from a solitary JB6 P+ cell, which should be important for the tumor 
promotion process.  Although the suppression of cloning efficiency was more effective after 
baicalein treatment than that after siRNA transfection, this difference may be attributable to the 
transfection efficiency of siRNA. 
 
p12-LOX independent clonal proliferation of malignant cancer cells 
To investigate whether p12-LOX is required for the tumor promotion step in other tissues, the 
expression of p12-LOX in gastric tumors of K19-Wnt1/C2mE mice (5) as well as intestinal polyps 
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of ApcΔ716 mice was examined (26).  Interestingly, the p12-LOX expression was significantly 
induced in both gastric and intestinal tumor tissues (Figure 6C), suggesting the role of p12-LOX 
in tumorigenesis also in the gastrointestinal tract.  Therefore, the cloning efficiency of gastric 
cancer cells (AGS and Kato-III) and colon cancer cells (DLD-1, SW480, and HCT-116) was 
examined.  The treatment with baicalein at 5 μM significantly decreased the cloning efficiency of 
SW480 cells, although the colonies still formed in 44% of the plate wells (Figure 6D).  The 
cloning efficiencies in other cell lines did not show significant decrease by the inhibition of 
p12-LOX.  Accordingly, it is possible that progressing cancer cells acquire the ability for 
p12-LOX-independent proliferation from a solitary cell, unlike JB6 P+ cells.  
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Discussion 
Accumulating evidence indicates that expression of p12-LOX is induced in several types of 
cancer tissues, whereas its expression is absent or weak in the normal tissues (6).  Moreover, 
p12-LOX expression increases in the advanced stage of cancer tissues, and the p12-LOX pathway 
is involved in the suppression of apoptosis, induction of cell survival, and angiogenesis 
(10,15,19,21).  These results suggest that the p12-LOX pathway plays a role in tumor 
development, progression and metastasis.  In addition to these results, the present study 
demonstrated, by pharmacological and genetic experiments, that p12-LOX pathway is required 
for tumor promotion in mouse epidermal cell transformation.  This is consistent with a previous 
report that disruption of the p12-LOX gene in mice suppresses the development of squamous cell 
carcinoma caused by an initiation/promotion protocol (23).  Moreover, the present study has 
shown that treatment with 12(S)-HETE, a metabolite of p12-LOX, further increases the number 
of soft agar colonies in TPA-treated JB6 P+ cells.  Accordingly, it is possible that formation of 
12(S)-HETE functions as a rate-limiting factor for tumor promotion in epidermal cell 
transformation.  This suggests that the induction level of p12-LOX may be positively correlated 
with the efficiency of tumor promotion.   
It has been shown that baicalein, a p12-LOX, inhibitor induces apoptosis in several types of 
cancer cells (13,15-17).  However, baicalein treatment at the concentration used in this study (5 
μM) showed only mild suppressive effect on cell proliferation when 103 JB6 P+ cells were plated 
in the microplate well.  When the number of plating cells was reduced to 102 cells, however, 
baicalein treatment at 5 μM significantly suppressed proliferation.  Moreover, the cloning 
efficiency of JB6 P+ cells was suppressed dramatically by the same concentration of baicalein.  
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These results collectively indicate that 12(S)-HETE is required for the proliferation of small 
number of cells or a single cell.  In the promotion step of tumorigenesis, the original “initiated” 
single cell or a small number of promoted cells needs to proliferate to form cluster of tumor cells.  
Accordingly, it is possible that the p12-LOX/12(S)-HETE pathway plays a key role in clonal 
proliferation of initiated cells during the promotion step.  In contrast, the cloning efficiency of 
malignant gastric and colon cancer cells was not affected by inhibition of p12-LOX.  It is possible 
that tumor cells derived from progressed cancer tissues have already acquired an ability of 
12(S)-HETE-independent proliferation from a single cell.   
These experiments showed that the expression of p12-LOX is induced in epidermal cells 
by stimulation with TNF-α, suggesting that an inflammatory host response induces p12-LOX 
expression through TNF-α/NF-κB pathway.  It has been shown that TPA stimulation also 
activates NF-κB in JB6 P+ cells (31), which is required for transformation (29,30).  It has been 
established that inflammation plays an important role in cancer development (32).  Genetic 
studies have demonstrated that the activation of the TNF-α/NF-κB pathway is required for tumor 
development in the mouse colon and liver through the suppression of apoptosis in tumor cells and 
the induction of growth factors from stromal cells (33,34).  Importantly, the expression of 
p12-LOX is induced not only in epidermal tumor cells but also in gastrointestinal tumors where 
an inflammatory response is associated (4,5).  Accordingly, it is possible that p12-LOX is one of 
the tumor promoting factors induced by inflammatory responses through the TNF-α/NF-κB 
pathway in various types of tumors.  It has been reported that AP-1 and NF-κB play a critical role 
in transformation of JB6 P+ cells, and activity of these factors is downregulated in JB6 P− cells 
(30,31).  Our results indicate that the deficiency of p12-LOX in JB6 P− cells contributes to a 
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resistant phenotype to tumor promoter-induced transformation.  Reactive oxygen species (ROS) 
also stimulate the neoplastic transformation of JB6 cells by activating AP-1 and NF-κB (31).  
Moreover, p12-LOX has also been reported to play a role in the ROS generation in neuroblastoma 
cells (35).  Accordingly, it is possible that the inhibition of p12-LOX suppresses neoplastic 
transformation of JB6 P+ cells which is caused, at least in part, by the decrease of TPA-induced 
ROS generation. 
These effects of the p12-LOX pathway on tumor promotion are similar to those of the 
COX-2/PGE2 pathway in the gastrointestinal tumorigenesis.  The activation of Wnt/β-catenin 
signaling causes the development of intestinal microadenoma (26).  The subsequent induction of 
the COX-2/PGE2 pathway in the microenvironment around the microadenoma is required for 
proliferation of small number of adenoma cells (3,36).  Specifically, the inhibition of COX-2 or 
PGE2 signaling suppresses proliferation of tumor cells in microadenoma (36,37).  Importantly, 
these gastrointestinal tumors in mouse models also show the induction of the p12-LOX pathway 
as indicated in the present study.  Therefore, it is possible that p12-LOX and COX-2 are two 
important pathways for tumor cell proliferation in the early stages.  This is consistent with the 
findings of recent reports in which the polymorphism of either of COX-2 or p12-LOX was shown 
to be associated with an increased risk of colon cancer development (38).  Moreover, both COX-2 
expression and 12(S)-HETE synthesis are induced in mouse prostate tumors (39).  On the other 
hand, baicalein treatment failed to induce a regression of the established tumors in the 
immunodeficient mice.  Accordingly, it is conceivable that the p12-LOX/12(S)-HETE pathway 
plays an important role particularly in the early promotion step like COX-2/PGE2 pathway, rather 
than in the progression stage.   
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In conclusion, the present results demonstrated that p12-LOX is required for tumor 
promotion during epidermal cell transformation, and 12(S)-HETE can accelerate tumorigenesis 
through enhancement of cloning efficiency.  The expression of p12-LOX is induced also in the 
gastrointestinal tumors, suggesting that the p12-LOX pathway is an effective target for 
chemoprevention against skin carcinogenesis as well as gastrointestinal cancer.  
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Figure Legends 
Figure 1.  The inhibition of p12-LOX in transformation-sensitive JB6 P+ cells suppresses colony 
formation in soft agar.  (A) Representative RT-PCR results for the p12-LOX, epidermal-type 
12-LOX (e12-LOX), leukocyte-type 12-LOX (l12-LOX), 5-LOX, 8-LOX are shown.  The 
expression of p12-LOX is elevated in transformation-sensitive JB6 P+ cells, whereas it remains at 
the basal level in transformation-resistant JB6 P− cells.  The expression of other LOX members is 
at the same level between JB6 P+ and JB6 P− cells.  Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as internal control.  JB6 P+ and P− cells were stimulated with TPA (10 
ng/ml) for 24 hours, and the mRNA levels were examined by RT-PCR chronologically at the 
respective time points indicated.  Relative band intensity of p12-LOX to the level at 0 h is 
indicated.  (B) Representative photographs of soft agar cultures of JB6 P+ (top) and JB6 P− 
(bottom) cells are shown (Giemsa staining).  TPA-treatment (10 ng/ml) induced soft agar colony 
formation in JB6 P+ cells (top, second panel from left) but not in JB6 P− cells (bottom, second 
panel from left).  Cells were treated with NDGA (5 μM), baicalein (5 μM), or AA-861 (10 μM) in 
the presence of TPA (right 3 panels).  Note that treatment with a non-selective LOX inhibitor, 
NDGA and a selective p12-LOX inhibitor, baicalein resulted in significant suppression of soft 
agar colony formation, whereas the 5-LOX inhibitor, AA-861 treatment did not.  (C) The mean 
number of colonies per field (mean ± S.D.) is shown.  Treatments of the cells (drug treatment or 
siRNA transfection) are indicated below the histogram.  *, P < 0.05 versus no-drug control of 
TPA-stimulated JB6 P+ cells.  (D) Representative RT-PCR for p12-LOX in the 
siRNA-transfected JB6 P+ cells is shown.  GAPDH was used as an internal control.  (E) 
Immunoblotting for p12-LOX in the siRNA-transfected JB6 P+ cells is shown.  β-Actin was used 
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as an internal control.   
 
Figure 2.  The inhibition of p12-LOX does not affect the tumor growth of JB6 P+ cells in vivo.  
(A) Photographs of TPA-stimulated JB6 P+ tumors developed in nude mice before (left) and after 
(right) baicalein treatment (20 mg/kg/day) at 26 and 40 days after the inoculation of tumor cells, 
respectively.  (B) The tumor volume changes from day 25 to day 40 (mean ± S.E.) is shown.  
Solid lines indicate baicalein-treated mouse tumors, while dashed lines show no-drug control 
mouse tumors.  (C) Representative photograph of BrdU incorporation (1 h) in the 
baicalein-treated tumor (bottom) and no-drug control tumor (top).  Bars indicate 100 μm.  Note 
that BrdU incorporation has increased in both baicalein treated- and untreated-mouse tumors. (D) 
Tumor volume at 1 week after palpable tumor developed in the baicalein-treated mice (from day 
7) and no-treated mice (mean ± S.E.) is shown. 
 
Figure 3.  Treatment with 12(S)-HETE enhances TPA-induced neoplastic transformation of JB6 
P+ cells.  (A) Representative photographs of soft agar cultures are shown (Giemsa staining).  
TPA-negative control cells (left), TPA-stimulated and baicalein-treated cells (center), and 
TPA-stimulated but baicalein-untreated cells (right).  The cells were pre-treated with 
12(S)-HETE at 0.1 μM (middle panels) and 1 μM (bottom panels).  Note that treatment with 
12(S)-HETE restored soft agar colony formation of baicalein-treated JB6 P+ cells (center panels).  
The number of colonies increased by 12(S)-HETE even in the baicalein-untreated JB6 P+ cells 
(right panels).  (B) The mean number of colonies per field is shown (mean ± S.D.).  Treatments of 
the cells are indicated below the histogram.  *, P < 0.05 versus 12(S)-HETE-untreated control of 
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each group. 
 
Figure 4. p12-LOX pathway is not required for TNF-α induced NF-κB activation, but is induced 
by TNF-α stimulation.  (A) Relative NF-κB activity to the untreated JB6 P− level is shown (mean 
± S.D.).  Treatments of the cells are indicated below the histogram.  *, P < 0.05 versus 
TNF-α-untreated level of JB6 P− and JB6 P+ cells, respectively.  †, P < 0.05.  (B) Representative 
RT-PCR results for p12-LOX in the TNF-α-simulated JB6 cells are shown.  The expression of 
p12-LOX is induced both in JB6 P+ and P− cells by TNF-α stimulation.  GAPDH was used as 
internal control.   
 
Figure 5.  Inhibition of p12-LOX significantly suppresses JB6 P+ cell proliferation when cells 
are plated at a low density.  Relative cell densities to no-drug control at day 4 (left) and day 6 
(right) after plating are shown (MTT assay, mean ± S.D.).  Open bars indicate relative cell density 
in the wells plated with 103 cells, whereas black bars indicate 102 cells.  Note that treatment with 
NDGA (5 μM) and baicalein (5 μM) suppressed proliferation significantly in the wells plated 
with 102 cells compared to that with 103 cells.  *, P < 0.05 versus no-drug control of the same 
cell-number group; and †, P < 0.05 versus 103 cell-plated well of the same drug group.   
 
Figure 6.  Inhibition of p12-LOX suppresses the cloning efficiency of JB6 P+ cells.  (A) 
Representative photographs of a microplate at 14 days after plating with no drug control, siRNA 
transfected, and baicalein treated cells (left to right), in which a single cell was seeded in each 
well (Giemsa staining).  The wells containing proliferating cells are indicated with a circle.  Note 
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that treatment with baicalein (5 μM) dramatically suppressed the cloning efficiency.  (B) The 
cloning efficiency of JB6 P+ cells is indicated as histogram (mean ± S.D.).  Treatments of the 
cells are indicated below the histogram.  *, P < 0.05 versus baicalein-untreated control of each 
group.  (C) Expression of p12-LOX is induced in gastric and intestinal tumors developed in 
K19-Wnt1/C2mE mice and ApcΔ716 mice, respectively.  Representative RT-PCR results are shown.  
T indicates tumor, while N indicates adjacent normal tissue.  GAPDH was used as internal control.  
(D) The cloning efficiencies of gastric and colon cancer cells are indicated as histogram (mean ± 
S.D.).  Treatments of the cells are indicated below the histogram.  *, P < 0.05 versus 
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